This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veru (VERU) delivered earnings and revenue surprises of -16.67% and 12.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
What Makes Veru (VERU) a New Buy Stock
by Zacks Equity Research
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 35% and 59.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0% and 3.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of 23.68% and 4.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 15.79% and 4.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs
by Zacks Equity Research
Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.
Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Veru (VERU) This Earnings Season?
by Zacks Equity Research
Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Veru Inc. (VERU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports live TV streaming platform.
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -51.21% in 4 Weeks, Here's Why You Should You Buy the Dip in Veru Inc. (VERU)
by Zacks Equity Research
Veru Inc. (VERU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -21.05% and 50.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?